Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2005;112:1428-1434
Published online before print August 29, 2005, doi: 10.1161/CIRCULATIONAHA.104.508465
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
112/10/1428    most recent
CIRCULATIONAHA.104.508465v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Anand, I. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Anand, I. S.
Related Collections
Right arrow Congestive
Right arrow Risk Factors

(Circulation. 2005;112:1428-1434.)
© 2005 American Heart Association, Inc.


Heart Failure

C-Reactive Protein in Heart Failure

Prognostic Value and the Effect of Valsartan

Inder S. Anand, MD, FRCP, DPhil (Oxon); Roberto Latini, MD; Viorel G. Florea, MD; Michael A. Kuskowski, PhD; Thomas Rector, PhD; Serge Masson, PhD; Stefano Signorini, BiolD; Paolo Mocarelli, MD; Allen Hester, PhD; Robert Glazer, MD; Jay N. Cohn, MD, for the Val-HeFT Investigators

From VA Medical Center (I.S.A., T.R.) and University of Minnesota (I.S.A., V.G.F., J.N.C.), Minneapolis, Minn; Geriatric Research, Education and Clinical Center (M.A.K.), VA Medical Center, Minneapolis, Minn; Istituto di Ricerche Farmacologiche Mario Negri (R.L., S.M.), Milan, Italy; Department of Medicine, New York Medical College (R.L.), Valhalla, NY; Milano-Bicocca University (S.S., P.M.), Department of Laboratory Medicine-Desio Hospital, Desio, Milan, Italy; and Novartis Pharmaceuticals Corporation (A.H., R.G.), East Hannover, NJ.

Correspondence to Inder S. Anand, MD, VA Medical Center, Cardiology 111-C, One Veterans Dr, Minneapolis, MN 55417. E-mail anand001{at}umn.edu

Received September 22, 2004; revision received May 11, 2005; accepted June 2, 2005.

Background— The role of C-reactive protein (CRP) in heart failure is not well studied. We assessed the prognostic value of CRP in patients randomized in Val-HeFT (Valsartan Heart Failure Trial) and studied changes in CRP that were associated with valsartan.

Methods and Results— Characteristics of patients with baseline CRP levels above and below the median value were compared. Univariable and multivariable Cox proportional hazards regression models were used to examine the relationship of CRP to mortality and morbidity. Interactions were tested to determine whether differences in CRP changes from baseline to 4 and 12 months between groups randomly assigned to valsartan or placebo depended on baseline ACE inhibitor use. Median plasma CRP was 3.23 mg/L (interquartile range 1.42 to 7.56 mg/L), which is higher than in the general population. Patients with CRP above the median had features of more severe heart failure than those with CRP levels below the median. The cumulative likelihood of death and first morbid event increased with increasing quartile of CRP. Relative to the lowest CRP quartile, the risk of mortality (hazard ratio 1.51, 95% CI 1.2 to 1.9) and first morbid event (hazard ratio 1.53, 95% CI 1.28 to 1.84) was increased in the highest CRP quartile in multivariable models. CRP added incremental prognostic information to that provided by brain natriuretic peptide alone. CRP did not change significantly over time in the placebo group; however, after 12 months, valsartan was associated with a decrease in CRP in patients not receiving ACE inhibitors but not in those receiving ACE inhibitors at 12 months.

Conclusions— CRP is increased in heart failure. Higher levels are associated with features of more severe heart failure and are independently associated with mortality and morbidity. The ability of treatments to reduce CRP levels and the prognostic importance of reducing CRP require further study.


Key Words: heart failure • C-reactive protein • prognosis • angiotensin receptor blockers • inflammation




This article has been cited by other articles:


Home page
The Annals of PharmacotherapyHome page
S. de Denus, M. Zakrzewski-Jakubiak, M.-P. Dube, F. Belanger, S. Lepage, M.-H. Leblanc, D. Gossard, A. Ducharme, N. Racine, L. Whittom, et al.
Effects of AGTR1 A1166C Gene Polymorphism in Patients with Heart Failure Treated with Candesartan
Ann. Pharmacother., July 1, 2008; 42(7): 925 - 932.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
R. C Parish and J. D Evans
Inflammation in Chronic Heart Failure
Ann. Pharmacother., July 1, 2008; 42(7): 1002 - 1016.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
P. van der Meer, D. J. Lok, J. L. Januzzi, P. W. B.-A. de la Porte, E. Lipsic, J. van Wijngaarden, A. A. Voors, W. H. van Gilst, and D. J. van Veldhuisen
Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients
Eur. Heart J., June 2, 2008; 29(12): 1510 - 1515.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
P. Elliott
Relevance of platelet activation in obstructive hypertrophic cardiomyopathy
Heart, June 1, 2008; 94(6): 688 - 689.
[Full Text] [PDF]


Home page
NEJMHome page
E. Braunwald
Biomarkers in Heart Failure
N. Engl. J. Med., May 15, 2008; 358(20): 2148 - 2159.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
G. Casaclang-Verzosa, B. J. Gersh, and T. S.M. Tsang
Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation.
J. Am. Coll. Cardiol., January 1, 2008; 51(1): 1 - 11.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. van der Harst, G. van der Steege, R. A. de Boer, A. A. Voors, A. S. Hall, M. J. Mulder, W. H. van Gilst, D. J. van Veldhuisen, and on behalf of the MERIT-HF Study Group
Telomere Length of Circulating Leukocytes Is Decreased in Patients With Chronic Heart Failure
J. Am. Coll. Cardiol., April 3, 2007; 49(13): 1459 - 1464.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
L. C. van Vark, I. Kardys, G. S. Bleumink, A. M. Knetsch, J. W. Deckers, A. Hofman, B. H.Ch. Stricker, and J. C.M. Witteman
Lipoprotein-associated phospholipase A2 activity and risk of heart failure: the Rotterdam Study
Eur. Heart J., October 1, 2006; 27(19): 2346 - 2352.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
S. Masson, R. Latini, I. S. Anand, T. Vago, L. Angelici, S. Barlera, E. D. Missov, A. Clerico, G. Tognoni, J. N. Cohn, et al.
Direct Comparison of B-Type Natriuretic Peptide (BNP) and Amino-Terminal proBNP in a Large Population of Patients with Chronic and Symptomatic Heart Failure: The Valsartan Heart Failure (Val-HeFT) Data
Clin. Chem., August 1, 2006; 52(8): 1528 - 1538.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
P. M Ridker, E. Danielson, N. Rifai, R. J. Glynn, and for the Val-MARC Investigators
Valsartan, Blood Pressure Reduction, and C-Reactive Protein: Primary Report of the Val-MARC Trial
Hypertension, July 1, 2006; 48(1): 73 - 79.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
W.H. W. Tang and G. S. Francis
The Year in Heart Failure
J. Am. Coll. Cardiol., December 6, 2005; 46(11): 2125 - 2133.
[Full Text] [PDF]